News | March 25, 2009

Siemens Highlights High Sensitivity C-Reactive Protein Test

March 25, 2009 - Siemens Healthcare Diagnostics’ C-reactive protein (hsCRP) test is cleared by the FDA for use as a predictor of risk for cardiovascular disease, and educational materials about the cardiac utility of the hsCRP test will be available in the company's booth (#1842) at the American College of Cardiology’s (ACC) Annual Scientific Session, March 29-31 in Orlando, FL.

The test was differentiated as the CardioPhase hsCRP test, and cleared with the cardiac-specific claim in January 2004 for use on the BN nephelometry systems. With the launch of this test on its ADVIA chemistry systems, Siemens extends use of a cardiac-specific hsCRP test across six leading-brand instrument platforms.

The JUPITER trial (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) specifically investigated the effect of statin therapy in apparently healthy individuals. The patients tested had low LDL cholesterol levels (2 mg/L), as determined by Siemens' BN II CardioPhase hsCRP test(1). The JUPITER trial concluded early because the statin therapy was significantly more beneficial than placebo in reducing cardiovascular morbidity and mortality by 43 percent(2).

The FDA has cleared all of Siemens' hsCRP tests for both risk assessment of future cardiovascular disease and risk stratification for the prognosis of recurrent cardiac events. When used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes, hsCRP measurements may also be useful as an independent marker of prognosis of recurrent events in patients with stable coronary disease or acute coronary syndrome.

Siemens' cardiac-specific hsCRP test is now available across multiple platforms including the BN nephelometry systems, Dimension and Dimension Vista integrated systems, the Stratus CS Acute Care Diagnostic System, ADVIA chemistry systems and the IMMULITE immunoassay systems.

(1) Glynn, MacFadyen, Ridker. Clinical Chemistry 2009; 55:2; pages 305-312.

(2) Ridker PM, et al. New England Journal of Medicine 2008; 359; pages 2195-2207.

For more information: www.siemens.com/healthcare.

Related Content

New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
PTSD Alone Does Not Increase Heart Disease Risk in Veterans
News | Cardiac Diagnostics | February 20, 2019
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...
Hormone Therapy May Increase Cardiovascular Risk During Gender Transition
News | Cardiac Diagnostics | February 18, 2019
Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular...
IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction
News | Cardiac Diagnostics | February 15, 2019
IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing...
Nearly Half of All U.S. Adults Have Cardiovascular Disease
News | Cardiac Diagnostics | January 31, 2019
January 31, 2019 — Nearly half (48 percent, 121.5 million in 2016) of all adults in the United States have some type
Frequent Red Meat Consumption Triples Levels of Chemical Associated With Heart Disease
News | Cardiac Diagnostics | January 23, 2019
Researchers have identified another reason to limit red meat consumption: high levels of a gut-generated chemical...
Overlay Init